Albert David Ltd (ALBERTDAVD) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap

Albert David Share Price

782.35 6.90 0.89%
as on 05-Dec'25 12:17

Albert David Ltd (ALBERTDAVD) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524075 | NSE: ALBERTDAVD | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Albert David

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Albert David stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
442.6 Cr.
52-wk low:
763.9
52-wk high:
1,537.2

Is Albert David Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Albert David: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Albert David Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 46.5%14.3%7.9%20.6%13.7%12%18.1%17.1%27.9%6.5%-
Value Creation
Index
2.30.0-0.40.50.0-0.10.30.21.0-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 323295290317321247314342362346316
Sales YoY Gr.--8.5%-1.7%9.3%1.1%-22.9%26.7%9%6.1%-4.6%-
Adj EPS 33.323.711.42636.43757.162.9130.330.8-26.4
YoY Gr.--28.8%-52%128.7%39.8%1.6%54.4%10.1%107.2%-76.3%-
BVPS (₹) 239.8320.7325.8368.7390.4428.2489.7545.9671.1687.7690.2
Adj Net
Profit
1913.56.514.920.821.132.635.974.317.6-15
Cash Flow from Ops. 6819.93031.930.336.640.410.545.5-28.4-
Debt/CF from Ops. 0.31.50.900.100.10.50.1-0.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.8%1.5%3.3%-4.6%
Adj EPS -0.9%-3.3%-18.6%-76.3%
BVPS12.4%12%12%2.5%
Share Price 7.1% 11.8% 8.5% -43.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
16.68.53.57.59.6912.412.121.44.5-3.8
Op. Profit
Mgn %
9.76.65.99.410.67.813.113.2131.2-3.9
Net Profit
Mgn %
5.94.62.24.76.58.510.410.520.55.1-4.8
Debt to
Equity
0.20.20.200000000
Working Cap
Days
161194212193190227183201201232209
Cash Conv.
Cycle
62624732283627323139146

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Albert David Ltd.

Standalone Consolidated
TTM EPS (₹) -26.4 -
TTM Sales (₹ Cr.) 316 -
BVPS (₹.) 690.2 -
Reserves (₹ Cr.) 388 -
P/BV 1.12 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 763.90 / 1537.20
All Time Low / High (₹) 3.15 / 1752.95
Market Cap (₹ Cr.) 443
Equity (₹ Cr.) 5.7
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Albert David:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Albert David - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Albert David

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales323295290317321247314342362346
Operating Expenses 291277275288290228273297315343
Manufacturing Costs66545655543350656261
Material Costs60566075747087879182
Employee Cost 828386909083858188109
Other Costs 84847368724350647490
Operating Profit 3118162931194144473
Operating Profit Margin (%) 9.7%6.1%5.4%9.2%9.5%7.8%13.1%13.0%13.0%0.9%
Other Income 216102171716155830
Interest 2111111101
Depreciation 9887889977
Exceptional Items 41000000000
Profit Before Tax 63261643292747519725
Tax 15106161051215228
Profit After Tax 48161027192235367517
PAT Margin (%) 14.9%5.4%3.4%8.4%6.0%8.9%11.2%10.6%20.8%5.0%
Adjusted EPS (₹)84.128.017.246.733.638.861.863.4132.230.1
Dividend Payout Ratio (%)7%20%32%13%21%15%15%14%9%17%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 137183186210223244279312383392
Share Capital 6666666666
Reserves 131177180205217239274306377387
Minority Interest0000000000
Debt20302801144210
Long Term Debt0000100000
Short Term Debt20302800044210
Trade Payables27273230382530323438
Others Liabilities 81110116135136135161165185184
Total Liabilities 265351361376398405475512604625

Fixed Assets

Gross Block172221192192212212223222230251
Accumulated Depreciation127134109115121128135142147152
Net Fixed Assets 44878377918488808399
CWIP 5955211372
Investments 485968113122138183193273260
Inventories49514344433639514464
Trade Receivables35332722301925302927
Cash Equivalents 23152677351925312
Others Assets 609810910810492121131137171
Total Assets 265351361376398405475512604625

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 682030323037401146-28
PBT 22261643292747519725
Adjustment 6323-137-7-61-44-16
Changes in Working Capital 10319891911-269-29
Tax Paid -27-11-7-6-15-2-13-16-16-9
Cash Flow From Investing Activity -38-37-11-19-20-39-40-5-3323
Capex -6-20114-15-1-9-5-11-15
Net Investments -32-9-6-39-9-40-421-3334
Others -0-8-674311-1114
Cash Flow From Financing Activity -187-5-17-10-2-2-6-80
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -8000-1-10000
Interest Paid -2-1-0-0-1-0-0-0-0-0
Dividend Paid -6-1-4-4-9-0-3-5-5-7
Others -28-0-13-0-02-1-37
Net Cash Flow 12-1014-4-0-4-1-14-5

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)41.89.985.3313.448.859.4813.4612.2421.724.44
ROCE (%)46.4814.297.9420.613.7411.9918.117.127.876.54
Asset Turnover Ratio1.3510.870.90.870.650.750.730.690.6
PAT to CFO Conversion(x)1.421.2531.191.581.681.140.310.61-1.65
Working Capital Days
Receivable Days42413627283525282828
Inventory Days55595548475541454553
Payable Days157166181149167165115131133158

Albert David Ltd Stock News

Albert David Ltd FAQs

The current trading price of Albert David on 05-Dec-2025 12:17 is ₹782.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Albert David stood at ₹442.6.
The latest P/E ratio of Albert David as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Albert David as of 04-Dec-2025 is 1.12.
The 52-week high of Albert David is ₹1,537.2 and the 52-week low is ₹763.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Albert David is ₹315.8 ( Cr.) .

About Albert David Ltd

Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

  • Analgesics/AntiInflammatory
  • Anti-Bacterials
  •  Anti-Ulcerants
  •  Dermatologicals
  • Anxiolytics
  • Large Volume Parenteral
  •  Disposable Syringes & Needles
  • Herbal Drugs
  • Nutrition
  • Neurotropics
  •  Placental Extracts
  •  Anthelmintic
  • Haemostati
  • Cough Preparations
  • Laxatives
  • Skeletal Relaxants
  • Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

  • The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
  • It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
  •  Future expansion in the herbal product range will be focused in the area of women`s healthcare.
  • ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
  • Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
  •  The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×